Position in HALO
as of Mar 31, 2026
· filed May 4, 2026
Position Value
$1,330,860
+$685,319 QoQ
Shares Held
20,592
+114.7% QoQ
Ownership
0.017%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in HALO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Sigma Planning Corp holds $10,800,162 across 16 Biotechnology names. HALO ranks #3 (12.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
7,297 | $1,669,042 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,012 | $1,554,551 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
This page
|
20,592 | $1,330,860 | |
| 4 | SRPT |
Sarepta Therapeutics, Inc.
|
61,060 | $1,328,665 | |
| 5 | MRNA |
Moderna, Inc.
|
25,705 | $1,305,814 | |
| 6 | LGND |
Ligand Pharmaceuticals Inc
|
4,500 | $898,425 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,062 | $474,225 | |
| 8 | RNTX |
Rein Therapeutics, Inc.
|
348,677 | $453,280 |
All Filings in HALO
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,330,860 | 20,592 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $645,541 | 9,592 | Shares | Sole | 2026-01-30 | |
| 2025-09-30 | $575,792 | 7,851 | Shares | Sole | 2025-11-10 | |
| No filing history on record for this holder in this stock. | ||||||